NEW YORK — The Cigna Group (NYSE: CI) stands out among S&P 500 constituents, posting revenue and earnings growth that puts most peers to shame.
Cigna recorded 13.8 percent annual revenue growth over the last two years, driven by its Evernorth Health Services and Cigna Healthcare segments spanning pharmacy benefits, specialty care and medical plans.
Earnings growth has also cleared the peer-group bar. Cigna's earnings per share compounded at 12 percent annually over the last five years. At $282.1 billion in revenue, the company spreads administrative costs across a large membership base—a structural cost advantage competitors struggle to replicate. Cigna trades at $270.00, at 8.6x forward earnings—cheap for a compounder of this quality.
Not every large-cap name tells the same story. Snap-on (NYSE: SNA) and MSCI (NYSE: MSCI) are flashing warning signs that warrant attention.
Snap-on, founded in 1920, makes tools, equipment and diagnostics for vehicle repair, aerospace and the military. But organic revenue has disappointed for two straight years, earnings per share have gone nowhere, and returns on capital are eroding—a combination that suggests its core profit engine is losing power. At $430.23 and 20.2x forward earnings, the stock is not priced for a business in deceleration.
MSCI, whose roots date to 1792, sells indexes, analytics and decision-support tools to institutional investors worldwide. The company reported negative return on equity, a red flag for a business charging premium multiples. At $571.81 and 27x forward earnings, the market is pricing in a recovery that the financials have not yet delivered. That is a risk position, not a value one.
The spread in fundamentals among Cigna, Snap-on and MSCI illustrates why index-level analysis obscures as much as it reveals. At 8.6x forward earnings, CI offers the most asymmetric setup of the three.
